Allergy & Immunologyclinical trialDisease-Modifying Therapy
Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study
By MedXY|Apr 22, 2026
Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c
